Use of amifostine in the treatment of recurrent solid tumours in children.
Τίτλος | Use of amifostine in the treatment of recurrent solid tumours in children. |
Publication Type | Journal Article |
Year of Publication | 2007 |
Authors | Sidi, V., Arsos G., Papakonstantinou E., Hatzipantelis E., Fragandrea I., Gombakis N., & Koliouskas E. |
Journal | Hippokratia |
Volume | 11 |
Issue | 1 |
Pagination | 25-9 |
Date Published | 2007 Jan |
ISSN | 1790-8019 |
Abstract | AIM: Preclinical and clinical evaluation of amifostine (AMI) administration in conjunction with systemic chemotherapy supports its role as a cytoprotective agent of normal tissues without loss of impairing the antitumour effectiveness of chemotherapeutic agents. Since only a limited number of clinical studies has been performed using AMI in paediatric pts with malignancies we investigated the protective effect of AMI against carboplatin-induced myelotoxicity and nephrotoxicity in a paediatric group of patients. |
Alternate Journal | Hippokratia |
PubMed ID | 19582173 |
PubMed Central ID | PMC2464265 |